The Special Access Programme (SAP) provides access to nonmarketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radio-pharmaceutical products not approved for sale in Canada.
The Special Access Programme provides Canadian patients access to Panhematin and Normosang - a treatment for patients with acute porphyria. Alberta, Ontario and Quebec outline access programs below. The other provinces and territories can use the Special Access Program as requested by physicians.